Mangalam Drugs Financials
| MANGALAM | 106.68 0.21 0.20% |
Operating Margin 0.0564 | Profit Margin 0.0088 | Return On Equity (0.06) |
Mangalam | Select Account or Indicator |
Understanding current and past Mangalam Drugs Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Mangalam Drugs' financial statements are interrelated, with each one affecting the others. For example, an increase in Mangalam Drugs' assets may result in an increase in income on the income statement.
Please note, the presentation of Mangalam Drugs' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Mangalam Drugs' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Mangalam Drugs' management manipulating its earnings.
Mangalam Drugs Stock Summary
Mangalam Drugs competes with MRF, Honeywell Automation, Page Industries, and 3M India. Mangalam Drugs is entity of India. It is traded as Stock on NSE exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | India Stock View All |
| Exchange | National Stock Exchange of India |
| ISIN | INE584F01014 |
| Business Address | Rupam Building, Mumbai, |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.mangalamdrugs.com |
| Phone | 91 22 6261 6200 |
You should never invest in Mangalam Drugs without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Mangalam Stock, because this is throwing your money away. Analyzing the key information contained in Mangalam Drugs' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Mangalam Drugs Key Financial Ratios
Mangalam Drugs' financial ratios allow both analysts and investors to convert raw data from Mangalam Drugs' financial statements into concise, actionable information that can be used to evaluate the performance of Mangalam Drugs over time and compare it to other companies across industries.| Revenue | 3.67 B | ||||
| Gross Profit | 1.17 B | ||||
| EBITDA | 174.95 M | ||||
| Net Income | (90.72 M) | ||||
| Cash And Equivalents | 917.4 M |
Mangalam Drugs Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 2.3B | 2.6B | 3.3B | 3.6B | 3.3B | 2.1B | |
| Other Current Liab | 18.8M | 17.6M | 13.9M | 35.2M | 47.3M | 67.3M | |
| Net Debt | 503.4M | 691.1M | 859.6M | 796.1M | 975.9M | 676.8M | |
| Retained Earnings | 549.4M | 825.1M | 1.0B | 1.0B | 975.9M | 1.0B | |
| Cash | 16.3M | 5.9M | 19.5M | 26.8M | 11.9M | 10.3M | |
| Inventory | 648.4M | 585.9M | 1.2B | 1.4B | 1.2B | 642.9M | |
| Other Current Assets | 17.7M | 17.6M | 17.4M | 125.5M | 232.3M | 181.0M | |
| Total Liab | 1.3B | 1.3B | 1.8B | 2.1B | 2.0B | 1.2B | |
| Total Current Assets | 1.2B | 1.3B | 1.8B | 2.1B | 1.8B | 1.1B | |
| Accounts Payable | 565.9M | 426.8M | 545.5M | 970.7M | 658.9M | 446.2M | |
| Short Term Debt | 470.0M | 596.4M | 575.9M | 567.8M | 885.0M | 525.4M | |
| Net Receivables | 509.3M | 710.3M | 616.7M | 465.8M | 279.4M | 490.9M | |
| Other Liab | 122.9M | 141.8M | 174.3M | 168.1M | 193.3M | 117.7M | |
| Net Tangible Assets | 978.0M | 1.2B | 1.4B | 1.3B | 1.5B | 973.9M | |
| Other Assets | 1K | 63.0M | (1K) | 434.7M | 499.9M | 524.9M | |
| Long Term Debt | 3.5B | 68.8M | 3.6B | 187.7M | 133.5M | 126.9M | |
| Short Long Term Debt | 458.6M | 511.8M | 471.0M | 495.7M | 746.0M | 509.9M | |
| Long Term Debt Total | 3.5B | 4.2B | 3.7B | 3.0B | 3.4B | 3.3B | |
| Intangible Assets | 61.4M | 84.7M | 138.8M | 183.0M | 285.2M | 299.4M | |
| Net Invested Capital | 1.5B | 1.9B | 2.2B | 2.2B | 2.2B | 2.1B | |
| Net Working Capital | 97.1M | 243.4M | 473.6M | 412.3M | 119.4M | 113.4M |
Mangalam Drugs Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 65.0M | 63.2M | 72.0M | 127.5M | 139.2M | 146.1M | |
| Total Revenue | 2.8B | 3.8B | 4.5B | 3.7B | 3.7B | 2.6B | |
| Gross Profit | 837.8M | 1.2B | 1.4B | 1.2B | 188.1M | 178.7M | |
| Operating Income | 155.3M | 442.0M | 388.1M | 149.7M | 27.5M | 26.1M | |
| Ebit | 127.0M | 488.0M | 388.9M | 149.7M | 28.4M | 27.0M | |
| Ebitda | 209.2M | 579.8M | 491.4M | 259.5M | 174.9M | 249.0M | |
| Cost Of Revenue | 2.0B | 2.6B | 3.1B | 2.5B | 3.5B | 2.0B | |
| Income Before Tax | 62.5M | 395.2M | 277.3M | 22.1M | (110.7M) | (105.2M) | |
| Net Income | 82.5M | 279.7M | 196.6M | 12.7M | (90.7M) | (86.2M) | |
| Income Tax Expense | (20.0M) | 115.5M | 80.8M | 9.4M | (20.0M) | (19.0M) | |
| Research Development | 20.8M | 22.5M | 29.6M | 33.2M | 32.7M | 22.5M | |
| Tax Provision | 412.4M | 115.5M | 413.8M | 9.4M | (20.0M) | (19.0M) | |
| Interest Income | 262.9M | 647.2M | 644.3M | 291.6M | 335.3M | 391.1M | |
| Net Interest Income | (96.0M) | (93.3M) | (111.6M) | (127.5M) | (139.2M) | (146.1M) |
Mangalam Drugs Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Mangalam Drugs And. It measures of how well Mangalam is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Mangalam Drugs brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Mangalam had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Mangalam Drugs has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | 86.1M | 62.6M | (585.2M) | (203.6M) | 168.9M | 177.3M | |
| Change In Cash | 2.0M | (10.4M) | 13.6M | 7.3M | (15.0M) | (14.3M) | |
| Free Cash Flow | 236.2M | (38.9M) | (19.6M) | 116.1M | (79.2M) | (75.2M) | |
| Depreciation | 82.2M | 91.8M | 102.5M | 109.9M | 74.9M | 62.4M | |
| Other Non Cash Items | 104.4M | (12.1M) | 33.2M | 129.6M | (5.0M) | (4.8M) | |
| Capital Expenditures | 69.3M | 314.4M | 276.7M | 279.1M | 118.3M | 145.7M | |
| Net Income | 62.5M | 395.2M | 277.3M | 22.1M | (90.7M) | (86.2M) | |
| End Period Cash Flow | 16.3M | 5.9M | 19.5M | 26.8M | 11.8M | 10.3M | |
| Net Borrowings | (130.7M) | 120.2M | 141.4M | (38.7M) | (44.5M) | (42.2M) | |
| Change To Netincome | 84.4M | 103.4M | 113.9M | 139M | 159.9M | 128.1M |
Mangalam Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mangalam Drugs's current stock value. Our valuation model uses many indicators to compare Mangalam Drugs value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mangalam Drugs competition to find correlations between indicators driving Mangalam Drugs's intrinsic value. More Info.Mangalam Drugs And is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Mangalam Drugs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Mangalam Drugs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Mangalam Drugs And Systematic Risk
Mangalam Drugs' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mangalam Drugs volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Mangalam Drugs And correlated with the market. If Beta is less than 0 Mangalam Drugs generally moves in the opposite direction as compared to the market. If Mangalam Drugs Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mangalam Drugs And is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mangalam Drugs is generally in the same direction as the market. If Beta > 1 Mangalam Drugs moves generally in the same direction as, but more than the movement of the benchmark.
Mangalam Drugs And Total Assets Over Time
Mangalam Drugs Thematic Clasifications
Mangalam Drugs And is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
| Drugs | View |
Mangalam Drugs November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mangalam Drugs help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mangalam Drugs And. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mangalam Drugs And based on widely used predictive technical indicators. In general, we focus on analyzing Mangalam Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mangalam Drugs's daily price indicators and compare them against related drivers.
| Information Ratio | (0.24) | |||
| Maximum Drawdown | 10.97 | |||
| Value At Risk | (4.22) | |||
| Potential Upside | 2.64 |
Complementary Tools for Mangalam Stock analysis
When running Mangalam Drugs' price analysis, check to measure Mangalam Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangalam Drugs is operating at the current time. Most of Mangalam Drugs' value examination focuses on studying past and present price action to predict the probability of Mangalam Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangalam Drugs' price. Additionally, you may evaluate how the addition of Mangalam Drugs to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |